A New and Innovative Method for CO2 Removal in Anesthetic Circuits: Replacing Chemical Granulate

Not Applicable

Recruiting

• Conditions: Anesthesia
• Interventions: Device: memsorb

• Registration Number: NCT03014336
• Lead Sponsor: DMF Medical Incorporated

Brief Summary

The drawbacks of chemical CO2 absorbers include the production of compounds harmful to patients that also lead into increased cost and environmental impact, as well as the daily disposal of compound special waste. Sustainable management of general anesthesia is a growing concern. Continually diluting anesthetic circuits, and the disposal of chemical granulate are serious environmental problems.

Detailed Description

DMF Medical has developed a next-generation CO2 filter in order to address the safety issues with current chemical CO2 absorbers in anesthesia.

memsorb uses patented advanced medical membrane technology to filter CO2 from anesthetic circuits rather than absorbing via a chemical reaction.

This game changing technology relies on a polymeric membrane core (similar to the ones used in oxygenators for cardiac surgery) that selectively allows CO2 to leave the rebreathing system, while maintaining the anesthetic vapor in the circuit.

memsorb is a cartridge similar in size and shape to current solutions that simply clicks in place.

Study Timeline

• Study First Submitted: 2016-10-12
• Study Start: 2017-01
• Study First Submitted QC: 2017-01-05
• Study First Posted: 2017-01-09
• Status Verified: 2022-11
• Last Update Submitted: 2022-11-18
• Last Update Posted: 2022-11-21
• Primary Completion: 2024-12
• Study Completion: 2025-06

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 450

Inclusion Criteria

• American Society of Anesthesiologists Physical Status Class I, II, III (low-medium risk patient)
• English-speaking patients

Exclusion Criteria

• Self-reported as pregnant
• American Society of Anesthesiologists Physical Status Class IV (high risk patient)
• Patients scheduled for emergency surgery
• Documented respiratory disease, including COPD and severe asthma
• Documented elevated pressure in the brain (intra cranial pressure, ICP)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
memsorb	memsorb	Patients agree to receive standard care but using memsorb, the new CO2 filter evaluated in this study.

Primary Outcome Measures

Name	Time	Method
End Tidal CO2	Up to 12h	Concentration of carbon dioxide during expiratory cycle.

Trial Locations

Locations (2)

Queen Elizabeth II HSC, Halifax Infirmary Site; 🇨🇦 Halifax, Nova Scotia, Canada

McGill University Health Centre; 🇨🇦 Montréal, Quebec, Canada